PNC-27
p53-MRP peptide · p53(12-26)-penetratin · anti-cancer peptide 27
Last updated
At a glance
Overview
What PNC-27 Actually Is#
PNC-27 is an experimental oncolytic peptide — a 32-residue chimera fusing the HDM-2-binding region of p53 (residues 12–26) to a penetratin-style membrane-residency sequence. It earned its reputation in the cancer-research literature for a genuinely unusual mechanism: docking into surface-expressed HDM-2 on transformed cells and punching transmembrane pores that trigger rapid necrosis, while sparing untransformed cells that don't display HDM-2 at the plasma membrane.
This is the part the rest of the page has to be honest about: PNC-27 is not a physique, recovery, longevity, or aesthetics peptide. It has no documented role in muscle, fat loss, hair, skin, sleep, or sexual response. The community attention it gets comes almost entirely from users with a personal or family cancer concern who have read the Pincus group's papers and are self-experimenting outside the clinical trial system. The protocols circulating on r/Peptides and r/USPeptides are oncology-adjacent, not biohacking.
"PNC-27 binds avidly to HDM-2 in cancer cell membranes and kills these cells by forming transmembrane pores, while sparing untransformed cells lacking surface HDM-2." — Sarafraz-Yazdi et al., PNAS 2010
The sections below cover the membrane-HDM-2 mechanism in detail, the ~30-minute plasma half-life and what it implies for dosing frequency, documented preclinical infusion data versus the bolus subcutaneous protocols circulating in the gray market, the Miller 2025 ketone-synergy finding, reconstitution and storage handling (Met20 is an oxidation liability), and the hard contraindications — pregnancy, active oncology treatment, and renal or hepatic impairment — that aren't negotiable on a peptide with no human safety database.
How PNC-27 works
Surface HDM-2: The Tumor-Selective Target#
PNC-27's selectivity rests on a quirk of transformed cells. HDM-2 (the human MDM-2 homolog) is normally an intracellular E3 ligase that tags p53 for degradation — it lives in the nucleus and cytoplasm. In cancer cells, full-length HDM-2 gets aberrantly trafficked to the plasma membrane and displayed on the cell surface, while untransformed cells express 4–9× less surface HDM-2. The p53(12-26) segment of PNC-27 adopts the same α-helical conformation it occupies in the native p53-HDM-2 crystal complex and docks into this surface-displayed HDM-2 as if it were docking inside the nucleus.
"PNC-27 binds avidly to HDM-2 in cancer cell membranes and kills these cells by forming transmembrane pores, while sparing untransformed cells lacking surface HDM-2." — Sarafraz-Yazdi et al., PNAS, 2010
The selectivity argument is relative, not absolute. When MCF-10-2A cells (normally PNC-27-resistant) are transfected to display membrane HDM-2, they become susceptible — confirming that surface HDM-2 is the entire ballgame.
Pore Formation and Necrotic (Not Apoptotic) Killing#
Once anchored, the amphipathic α-helix-loop-α-helix architecture of PNC-27 inserts into the lipid bilayer and forms transmembrane pores. The downstream signature is LDH release, loss of membrane integrity, and necrosis — without elevation of caspase-3/7. This is mechanistically distinct from nutlins and other small-molecule HDM-2 antagonists, which work intracellularly to liberate p53 and trigger apoptosis.
"Unlike previously described p53-derived peptides that induce apoptosis, PNC-28 and PNC-27 caused rapid necrosis, mediated by disruption of the plasma membrane via pore formation." — Bowne et al., Annals of Surgical Oncology, 2008
Practically: there is no apoptotic delay, no caspase cascade to inhibit, and no p53 pathway dependency. The peptide either docks and lyses or it doesn't.
p53-Independent Activity#
Because killing is membranolytic rather than transcriptional, PNC-27 works in p53-null lines — K562 leukemia, SAOS-2 osteosarcoma, and several pancreatic and melanoma lines that have lost functional p53 entirely. What predicts susceptibility is surface HDM-2, not p53 status.
"PNC-27 induced concentration-dependent loss of cell viability and marked necrosis in K562 leukemia cells, correlating with the presence of HDM-2 in their plasma membranes." — Davitt et al., Annals of Clinical and Laboratory Science, 2014
This decouples PNC-27 from the bulk of the p53-targeting drug literature and explains why it kills tumor types that have escaped p53-restoration strategies.
Penetratin Domain and Membrane Residency#
The C-terminal MRP (membrane-residency / penetratin) sequence — 17 residues borrowed from the antennapedia homeodomain — is what concentrates the peptide at the bilayer long enough to oligomerize and form a pore. Architecture matters: reversing the penetratin to the N-terminus abolishes the membranolytic effect and converts PNC-27 into a conventional p53-restoring apoptosis inducer. Any commercial product worth running must have the MRP on the C-terminus, which is one reason mass-spec confirmation on the COA is non-negotiable for this peptide.
A secondary consequence: internalized peptide that reaches mitochondria disrupts mitochondrial membranes as well, amplifying the necrotic signal beyond the initial plasma-membrane hit.
Half-Life Constraints on the Mechanism#
The mechanism is a contact-dependent, exposure-driven process — the peptide has to be present at the membrane long enough to oligomerize. With a plasma half-life of ~30 minutes and no half-life-extending modifications, a single daily bolus leaves target cells unexposed for >95% of the dosing interval. This is why the published efficacy data comes from continuous infusion via Alzet osmotic mini-pumps, not bolus injections.
"Continuous administration of PNC-28 via osmotic mini-pump led to significant inhibition of tumor growth in nude mice bearing human pancreatic cancer xenografts." — Michl et al., International Journal of Cancer, 2006
Community protocols that split dosing 2–3× daily are a partial workaround, but they don't fully replicate the continuous exposure profile that drove the preclinical results. The mismatch between PK and bolus dosing is the most likely explanation for inconsistent anecdotal outcomes.
Metabolic Sensitization by Ketone Bodies#
A recent in vitro finding extends the mechanism into the metabolic domain. In HeLa cervical cancer cells, addition of β-hydroxybutyrate and acetoacetate amplified PNC-27 cytotoxicity without affecting untransformed cervical cells.
"Addition of ketone bodies significantly enhanced the cytotoxic effect of PNC-27 against HeLa cells without affecting normal cervical cell viability." — Miller et al., Medical Research Archives, 2025
The proposed mechanism is that ketone bodies stress the already-compromised mitochondrial metabolism of transformed cells, lowering the threshold for membrane-mediated necrosis. This is in vitro data only — translation to in vivo or to human research contexts remains speculative — but it is the rationale behind community protocols that pair administration with a ketogenic dietary state or exogenous ketones.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 5–5 mg | Twice daily | Documented entry-level range |
| Mid | 5–10 mg | Twice daily | Most commonly studied range |
| High | 15–20 mg | Twice daily | The ~30-minute plasma half-life means single daily bolus dosing leaves the target tissue unexposed for the vast majority of the interval. Community protocols split into 2–3 daily injections; preclinical efficacy data comes from continuous infusion via osmotic mini-pump. |
Cycle length & outcomes
Documented cycle
3–4 weeks
Plateau after
4 wks
Cycle Length & Protocol Notes#
PNC-27 is not a peptide that rewards long, slow accumulation. The mechanism is acute and membranolytic — pores form on contact with surface-HDM-2-bearing cells, lysis happens fast, and the peptide is cleared in ~30 minutes. Cycles are short, intensive, and structured around frequency of exposure rather than total course length.
PNC-27 Dosage by Goal#
All published efficacy data is preclinical. The table below reflects gray-market research protocols documented in community references; community totals are lower than the rodent infusion work would predict on a mg/kg basis, but the trade-off is bolus subcutaneous delivery instead of osmotic-pump continuous infusion.
| Research Context | Cycle Length | Daily Dose | Split |
|---|---|---|---|
| Beginner / tolerance assessment | 14–21 days | 5 mg | 1× daily SubQ |
| Standard research protocol | 21–28 days | 10 mg | 5 mg 2× daily SubQ |
| Aggressive community protocol | 21–28 days | 15–20 mg | 5–7 mg 2–3× daily SubQ |
| Nebulized (exploratory) | 14–28 days | 5–10 mg | 1× daily, 3–5 mL sterile saline |
Why Frequency Matters More Than Total Dose#
The plasma half-life is ~30 minutes. A single daily 15 mg bolus leaves target tissue effectively unexposed for >95% of the 24-hour interval. The Michl 2006 pancreatic cancer work makes this point cleanly:
"Continuous administration of PNC-28 via osmotic mini-pump led to significant inhibition of tumor growth in nude mice bearing human pancreatic cancer xenografts." — Michl et al., Int J Cancer 2006
Continuous infusion is not realistic outside a research animal facility, so the community workaround is to split the daily total into 2–3 injections spaced 6–10 hours apart. This is the single most important protocol decision and the one most often gotten wrong.
Loading and Tapering#
There is no loading phase. There is no taper. PNC-27 is not hormonal, does not suppress an axis, and does not require ramp-up to saturate a receptor reserve — the mechanism is mass-action pore formation at the cell surface. The protocol starts at full dose and stops at full dose.
A short tolerance check (3–5 days at 5 mg once daily) is reasonable before stepping into a split-dose 10–15 mg/day course, primarily to identify injection-site reactions and any flu-like response before committing to a 21–28 day run.
Onset Timing#
There is no acute subjective signal — no flush, no pump, no sleep change, no "feel." A peptide acting on a small fraction of surface-HDM-2-displaying cells does not produce a felt drug effect. Anyone expecting one is reading the mechanism wrong.
Objective markers, where they apply to the research context, tend to shift on the order of 2–4 weeks. LDH is the most direct biomarker because the killing mode is necrotic:
"PNC-27 induced concentration-dependent loss of cell viability and marked necrosis in K562 leukemia cells, correlating with the presence of HDM-2 in their plasma membranes." — Davitt et al., Ann Clin Lab Sci 2014
LDH is also a non-specific marker, so it is read in context with CBC, CMP, and CRP rather than alone.
Cycle Length Ceiling#
Documented protocols cap at 3–4 weeks per course. Two reasons:
- Peptide stability. Reconstituted PNC-27 is good for roughly 14–21 days refrigerated before Met20 oxidation degrades activity. A single 30 mg vial at 10 mg/day runs out inside three days; the practical cycle length is governed by vial economics and reconstitution shelf-life as much as by biology.
- No long-term safety data. Selectivity in the Sarafraz-Yazdi PNAS work is a relative argument — transformed cells display 4–9× more surface HDM-2 than untransformed cells, not infinitely more:
"PNC-27 binds avidly to HDM-2 in cancer cell membranes and kills these cells by forming transmembrane pores, while sparing untransformed cells lacking surface HDM-2." — Sarafraz-Yazdi et al., PNAS 2010
Extending past 4 weeks is unsupported by any data and removes the rationale for a defined washout window.
Users running repeat courses typically allow 2–4 weeks washout between blocks, with bloodwork at the end of each course before deciding whether to repeat.
Bloodwork Cadence#
Standard panel at baseline and end-of-cycle:
- CBC with differential — peptide-mediated necrosis releases DAMPs; watch WBC and inflammatory shifts.
- CMP — renal and hepatic function, given that clearance pathways are inferred rather than measured.
- LDH — direct readout of necrotic lysis; useful trend marker, non-specific in isolation.
- CRP, ferritin — inflammatory load from cell turnover.
- Urinalysis — if subcutaneous injection sites trend toward induration or systemic signs appear.
For a 21–28 day course: baseline → mid-cycle (day 14) → end-of-cycle. For repeat blocks, a fresh baseline before each new course is the minimum.
Stack Considerations#
PNC-27 does not stack with physique compounds in any mechanistically meaningful way. Three pairings appear in community protocols:
- Ketogenic dietary state or exogenous ketones. The Miller 2025 in vitro data is the basis:
"Addition of ketone bodies significantly enhanced the cytotoxic effect of PNC-27 against HeLa cells without affecting normal cervical cell viability." — Miller et al., Med Res Arch 2025
In vitro on HeLa cells. Translation to in vivo human exposure is speculative, but the pairing is low-cost and biologically plausible.
-
BPC-157 or thymalin. Used adjunctively for tissue support and injection-site recovery. No mechanistic interaction with PNC-27 itself; treat as separate protocols sharing a calendar.
-
Chemotherapy regimens (paclitaxel in the Sookraj 2015 ex vivo ovarian work). This belongs in a registered clinical trial, not a self-directed protocol. Listed for completeness only.
AAS, SARMs, GH, and growth peptides are mechanistically unrelated and there is no published interaction data. The honest answer is that PNC-27 sits outside the physique-enhancement stack entirely.
Practical Cycle Summary#
- Standard course: 10 mg/day, split 5 mg AM / 5 mg PM SubQ, 21–28 days.
- Reconstitution: 3 mL bacteriostatic water per 30 mg vial → 10 mg/mL. Refrigerate immediately, use within 14–21 days, no freeze/thaw.
- No loading, no taper, no PCT.
- Bloodwork: baseline, day 14, end-of-cycle. CBC, CMP, LDH, CRP, ferritin.
- Washout: 2–4 weeks before any repeat block.
- Hard stop: active oncology treatment without coordination, pregnancy or pregnancy potential, renal or hepatic impairment, peptide hypersensitivity.
Risks & mistakes
Common (most users)#
- Injection-site reactions — redness, induration, or mild stinging at subcutaneous sites. PNC-27 is a membrane-active amphipathic peptide by design, so local irritation is more pronounced than with typical research peptides like BPC-157 or TB-500. Mitigation: rotate sites aggressively (no repeat depot within 7 days), keep the reconstituted volume small (10 mg/mL is comfortable), inject at room temperature rather than straight from the fridge, and consider ventral abdomen rather than thigh for lower irritation.
- Mild fatigue or flu-like feeling — most often in the first 3–5 days of a protocol, plausibly tied to DAMP release from necrotic cell turnover. Mitigation: front-load lower (5 mg/day for the first 3–5 days) before titrating to the target dose. Adequate hydration and a maintenance protein intake support clearance.
- Transient low-grade headache — reported anecdotally in community logs. Mitigation: dose-split rather than bolus, ensure sodium and fluid intake are not under-corrected, and avoid stacking with other novel peptides in the same window.
- No subjective "feel" — not an adverse effect, but worth flagging: PNC-27 produces no acute hedonic or somatic signal. Users expecting BPC-157-style "I feel something working" feedback often increase the dose inappropriately. Mitigation: anchor protocol decisions on bloodwork and predefined endpoints, not on subjective response.
Uncommon (dose-dependent or individual)#
- Pronounced local necrosis at the depot — at the upper end of community dosing (15–20 mg/day), repeated injection into the same site can produce a more lytic local reaction than typical peptide induration. Back off when: any site shows expanding erythema beyond ~2 cm, persistent tenderness past 72 hours, or pigmentation change. Switch sites and drop daily dose by 25–50%.
- Elevated LDH on bloodwork — mechanistically expected since membrane lysis releases LDH. Check: baseline CBC, CMP, and LDH prior to initiation, then at day 14 and day 28. Interpret with the mechanism in mind — a modest LDH rise on a membranolytic peptide is not the same signal it would be on a hepatology workup, but a 2×+ ULN rise warrants stopping and reassessing.
- Mild CRP / ferritin elevation — consistent with low-grade inflammation from cell-turnover debris. Check: inflammatory panel at baseline and end-of-cycle. Persistent elevation past the washout argues against repeating the course.
- GI upset, loose stool — uncommon, mostly reported in users who pair PNC-27 with aggressive ketogenic transitions on the strength of the Miller 2025 in vitro paper. Mitigation: stagger the dietary change rather than starting both interventions the same week.
- Sleep disturbance / vivid dreams — anecdotal, not mechanistically explained, not well-documented. Mitigation: shift the second daily injection earlier (no later than mid-afternoon).
Rare but serious#
- Systemic hypersensitivity / anaphylactoid reaction — any 32-mer peptide manufactured by gray-market vendors carries a non-zero risk of allergic response, compounded by purity variability. Warning signs: generalized urticaria, facial/lip swelling, wheeze, hypotension, or syncope within 30 minutes of an injection. Discontinue immediately.
- Off-target tissue toxicity — the selectivity argument rests on relative surface HDM-2 expression. Tissues with elevated proliferation (some benign hyperplasias, regenerating epithelium) theoretically sit closer to the threshold. Warning signs: unexplained organ-specific symptoms (RUQ pain, hematuria, prolonged GI bleeding) during a course. Stop, baseline labs, and do not reinitiate.
- Unanticipated interaction with active oncology treatment — additive cytotoxicity with paclitaxel was reported ex vivo (Sookraj et al. 2015), and the direction of interaction with other agents is unknown. Combined exposure outside a registered trial is the worst possible context — both for safety and for any meaningful interpretation of the result.
- Degraded / mis-synthesized product effects — Met20 oxidation and truncated synthesis have both been flagged in community vendor analysis. A mis-sequenced "PNC-27" may behave as an apoptosis inducer rather than a membranolytic (Bowne et al. 2008 on penetratin orientation), with entirely different toxicology. Warning signs: sharply different subjective or laboratory response on a new vial vs. the previous one from the same vendor.
Hard contraindications#
- Pregnancy and pregnancy potential — absolute. No reproductive toxicology exists for a membrane-active 32-mer; the mechanism is incompatible with placental safety assumptions.
- Lactation — absolute. No data on transfer; mechanism is incompatible with infant exposure.
- Active oncology treatment under a clinician's care — do not layer PNC-27 onto a chemotherapy, immunotherapy, or radiation regimen outside a registered trial. Interactions are uncharacterized; the result is uninterpretable to the treating oncologist; and ex vivo additivity with paclitaxel is documented but not safety-quantified (Sookraj et al. 2015).
- Renal or hepatic impairment — clearance pathways are unmapped. The default assumption (peptidase fragmentation plus renal clearance of fragments) means impaired clearance compounds exposure unpredictably.
- Known hypersensitivity to peptide products — prior reaction to any injected peptide is a stop-line for a compound with this little human safety data.
- Freeze/thaw-cycled or visibly degraded product — Met20 oxidation produces variants with unpredictable activity. Discard rather than dose.
Gender, fertility, and PCT considerations#
PNC-27 is not hormonal. It does not interact with the HPTA, aromatase, 5-α reductase, or androgen receptor pathways. No PCT is required and none is meaningful. No sex-based dosing differences are documented in the preclinical literature.
The one sex-specific line that does not move: pregnancy and pregnancy potential are an absolute contraindication. A membrane-active peptide of this class has no characterized teratogenic profile and no business in a reproductive context. Female users of childbearing potential running a course should have contraception in place for the duration and through at least one washout cycle. There is no equivalent fertility consideration documented on the male side, but the absence of data is not the same as evidence of safety.
FAQ — PNC-27
Research & citations
5 studies cited on this page.
Conclusion
PNC-27 is a highly selective membrane-lytic research peptide that targets HDM-2-expressing cells, with a mechanism backed by multiple preclinical studies. Its role is strictly oncologic — no credible data supports use in physique, skin, or longevity protocols.
Key takeaways:
- Typical research dose: 10–15 mg daily, divided into 2–3 subcutaneous injections to compensate for the ~30-min half-life
- Cycle length: 21–28 days per documented protocol, with 2–4 week washout between courses
- Route: Subcutaneous is favored for practicality; nebulized and IV routes are less validated and considered exploratory
- Stacking: Rarely stacked; some protocols pair with ketogenic state or exogenous ketones based on in vitro synergy, but evidence is preliminary
- Mechanism: Selective necrosis of surface-HDM-2-expressing cells, sparing normal tissue in preclinical models (Sarafraz-Yazdi et al. 2010; Davitt et al. 2014)
- Protocol design: Splitting doses and minimizing freeze/thaw cycles are critical for both efficacy and peptide stability
For targeted research on membrane-HDM-2-driven pathology, PNC-27 remains one of the most technically interesting — but narrowly focused — options in the experimental peptide space.